ANNA MARIA BUCCOLIERO

Dr. ANNA MARIA BUCCOLIERO

Meyer Children's Hospital, Florence, Tuscany, Italy
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2009 in Neuropathology
Verified
Journal Article
Closed access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
Alessandro FranchiAlessandro Franchi
Alessandro Franchi
FCFrancesca Castiglione
Francesca Castiglione
CGChiara F. Gheri
Chiara F. Gheri
FMFederico Mussa
Federico Mussa
GTGian L. Taddei
Gian L. Taddei

8 June 2007 in Cytopathology
Verified
Journal Article
Closed access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
CGC. F. Gheri
C. F. Gheri
FCF. Castiglione
F. Castiglione
FGF. Garbini
F. Garbini
ABA. Barbetti
A. Barbetti
GTG. L. Taddei
G. L. Taddei

22 May 2006 in Neuropathology
Verified
Journal Article
Closed access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
FGFlavio Giordano
Flavio Giordano
FMFederico Mussa
Federico Mussa
ATAntonio Taddei
Antonio Taddei
LGLorenzo Genitori
Lorenzo Genitori
GTGian Luigi Taddei
Gian Luigi Taddei

1 February 2010 in Neuropathology
Verified
Journal Article
Closed access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
FCFrancesca Castiglione
Francesca Castiglione
DDDuccio Rossi Degl'INnocenti
Duccio Rossi Degl'INnocenti
Alessandro FranchiAlessandro Franchi
Alessandro Franchi
MPMilena Paglierani
Milena Paglierani
GTGian Luigi Taddei
Gian Luigi Taddei

31 March 2022 in Genes
Verified
Journal Article
Open access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
LGLaura Giunti
Laura Giunti
SMSelene Moscardi
Selene Moscardi
FCFrancesca Castiglione
Francesca Castiglione
APAldesia Provenzano
Aldesia Provenzano
CCChiara Caporalini
Chiara Caporalini
Pediatric high-grade gliomas (pHGGs) encompass a heterogeneous group of tumors. Three main molecular types (H3.3 mutant, IDH mutant, and H3.3/IDH wild-type) and a number of subtypes have been identified. We provide an overview of pHGGs and present a mono-institutional series. We studied eleven non-related pHGG samples through a combined approach of routine diagnostic tools and a gene panel. TP53 and H3F3A were the most mutated genes (six patients each, 54%). The third most mutated gene was EGFR (three patients, 27%), followed by PDGFRA and PTEN (two patients each, 18%). Variants in the EZHIP, MSH2, IDH1, IDH2, TERT, HRAS, NF1, BRAF, ATRX, and PIK3CA genes were relatively infrequent (one patient each, 9%). In one case, gene panel analysis documented the presence of a pathogenic IDH2 variant (c.419G>A, p.Arg140Gln) never described in gliomas. More than one-third of patients carry a variant in a gene associated with tumor-predisposing syndromes. The absence of constitutional DNA did not allow us to identify their constitutional origin.

1 January 2007 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
ABANNA MARIA BUCCOLIERO
ANNA MARIA BUCCOLIERO
FCF. Castiglione
F. Castiglione
CGC.F. Gheri
C.F. Gheri
FGF. Garbini
F. Garbini
MFM. Fambrini
M. Fambrini
GTG.L. Taddei
G.L. Taddei